You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 103

    ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer

    SBC: ACTORIUS PHARMACEUTICALS, LLC            Topic: 100

    DESCRIPTION provided by applicant Breast cancer is the most common type of cancer in women between the ages of and and responsible for deaths annually If treated early five year survival rates for patients in the U S are between and but drop to once metastatic breast cancer has developed Thus there is a great need to develop more effective treatment strategies fo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. IMPROVING THE TREATMENT OF CONTAMINATED AQUIFERS BYDEVELOPING DIRECT-PUSH OXIDANT CANDLES WITH PNEUMATIC CIRCULATORS

    SBC: AirLIft Environmental LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Clean water is one of the most basic societal needs in the world Few situations incite more public outcry than when a community learns that their drinking water has been tainted Two of the biggest threats to groundwater quality in the U S are contamination from either chlorinated solvents or petroleum Left unattended the size and scope of the problems asso ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Bioassay Methods for Standardization of Immune Enhancing Dietary Supplements

    SBC: PSI (Phytochemical Services, Incorporated)            Topic: 213

    DESCRIPTION provided by applicant Clinical trials testing the potential health benefits of immune enhancing dietary supplements have produced inconsistent results A major problem contributing to these inconsistent outcomes is that these studies have used a wide variety of poorly characterized products Attempts to solve this product quality control problem using chemical standardization method ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Transmucosal Intra-Oral Drug Delivery System for THC

    SBC: ElSohly Laboratories, Incorporated            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this research project is to develop an effective, hot-melt extruded "Transmucosal Matrix Patch" (TMP) as a delivery system for Delta-9-Tetrahydrocannabinol (THC). THC will be incorporated into a stable, bioadhesive drug delivery system that is applied to a subject's buccal or labial oral mucosa. The controlled release of THC is delivered to ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  9. OTOREFLECTANCE ASSESSMENT OF MIDDLE-EAR FUNCTIONING

    SBC: Sonicom, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Otoreflectance (OR) is a new class of hearing test instruments utilizing acoustic signals presented and recorded in the ear canal. OR instruments address limitations in existing screening and diagnostic instruments in such areas as: (1) detecting otitis media, (2) predicting conductive hearing loss, (3) augmenting the newborn hearing screening protocol to test ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  10. A Dual Molecular/Targeting Therapy for PanCa

    SBC: SYNERGENE THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic Cancer (PanCa). Over 90% of these will die of the disease making PanCa one of the most devastating human malignancies. The current 5-year survival rate of less than 4% has changed little in the last 20 years despite improvements in therapy including the introduction of chem ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government